Human EGFRVIII Protein
Catalog No: EGFRVIII-HF001
- Species
- Human
- Expression System
- HEK293
- Tag
- an hFc (IgG1)
- Activity
- Activity verified
Product overview
Recombinant Human EGFRVIII Protein is expressed in HEK293 cells with an hFc (IgG1) tag at the C-terminus. It contains amino acid residues Leu25-Ser378 (accession: NP_001333870.1).
Product Details
- Molecular Aliases
- ErbB; EC 2.7.10; EC 2.7.10.1; EGFR; mENA; LEGFR; ERBB; ERBB1; HER1; PIG61; NISBD2;EC2.7.10; EC2.7.10.1
- Protein Length
- Leu25-Ser378
- Expression System
- HEK293
- Theoretical Molecular Weight
- The protein has a predicted MW of 64.58 kDa. Due to glycosylation, the protein migrates to 80-100 kDa based on Tris-Bis PAGE result.
- Purity
- > 95% as determined by Bis-Tris PAGE > 95% as determined by HPLC
- Endotoxin
- Less than 1 EU per μg by the LAL method.
- Buffer / Formulation
- Lyophilized from 0.22 μm filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization.
- State
- Lyophilized
- Storage Conditions
- -20 to -80°C for 12 months as supplied from date of receipt. -80°C for 3 months after reconstitution. Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.
- Reconstitution Advice
- Dissolve the lyophilized protein in distilled water. Please refer to the Certificate of Analysis for detailed instructions.
Data Display
Human EGFRVIII on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.
The purity of Human EGFRVIII is greater than 95% as determined by SEC-HPLC.
Immobilized Human EGFR VIII, hFc Tag at 0.5μg/ml (100μl/well) on the plate. Dose response curve for Biotinylated Anti-EGFRVIII Antibody, hFc Avi tag with the EC50 of 23.0ng/ml determined by ELISA. (QC Test)
Background
The epidermal growth factor receptor (EGFR) is overexpressed in a variety of human epithelial tumors, often as a consequence of gene amplification. Tumors with EGFR gene amplification frequently contain EGFR gene rearrangements, with the most common extracellular domain mutation being EGFRvIII. This mutation leads to a deletion of exons 2-7 of the EGFR gene and renders the mutant receptor incapable of binding any known ligand.
References
- Pedersen M W, Meltorn M, Damstrup L, et al. The type III epidermal growth factor receptor mutation Biological significance and potential target for anti-cancer therapy[J]. Annals of Oncology, 2001, 12(6):745-760.
Have questions about this product?
Our technical team can help with product selection, application questions and order support.